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Abstract
There has been considerable interest in the potential application of contact lenses for ocular drug delivery. This 
short communication provides an overview of the challenges faced by delivering drugs using contact lenses, highlights 
the solutions to limitations that have already been achieved, and describes the barriers that remain before commercial 
application can be realized. 
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Introduction
In the last few decades, potential applications of Contact Lenses 
(CL) beyond their use to correct refractive error have been investigated, 
including extensive research towards their use for ocular drug delivery. 
At present, topical eye drops remain the most common method 
for treating ocular disease, accounting for 90% of all ophthalmic 
formulations [1-4] and they are readily accepted by patients due to their 
convenience and cost effectiveness [1]. However, the ocular anatomy 
presents several barriers that prevent the effective and efficient delivery 
of medication from eye drops, including continuous tear dilution 
[5-7], dispersion and drainage during blinking and tear flow [5,7,8], 
non-specific absorption [1,5,7], and variable drug penetration [4]. This 
results in only 1-7% of the medication within an eye drop reaching the 
target tissue and exerting a therapeutic effect [8], with the remainder 
being either spilled onto the external ocular surface or absorbed 
systemically [9]. High turnover and poor absorption leads to the need 
for multiple dosing over extended periods to achieve therapeutic drug 
concentrations, leading to problems relating to patient compliance 
[10,11], as well as the potential for drug overdosing [12]. These 
limitations suggest that there is considerable room for improvement if 
efficient and effective treatment of anterior segment diseases is to occur. 
Contact lenses are often used in cases of ocular trauma or post-
surgery as so-called ‘bandage lenses’, as a means to manage pain and 
promote re-epithelialization [13]. Several commercially available 
CLs, including Pure Vision (balafilcon A, Bausch+Lomb), Acuvue 
2 (etafilcon A, Vistakon Inc.), Acuvue Oasys (senofilcon A, Vistakon 
Inc.), and Air Optix Night & Day (lotrafilcon A, Alcon) are FDA 
approved for use as bandage lenses [13-19]. In most cases, antibiotics 
and anti-inflammatory drugs are administered in conjunction with the 
CLs by adding the medication topically over the lens in situ [13,20]. 
This practice, although simple, is cumbersome and may not provide 
the desired effectiveness, with the uptake and release of the drug 
during such a process being unknown and uncontrolled. A survey of 
ophthalmic practitioners across the United States and Canada revealed 
that there is a strong interest in a CL that is specifically developed for 
use as a drug delivering therapeutic CL and that such a product would 
be well received by practitioners [13].
Advantages of using Contact Lenses
The use of CLs for ocular drug delivery overcomes several of the 
barriers that limit the effective use of eye drops. The placement of a 
CL on the cornea separates the tear film into pre-lens (exposed to the 
external environment) and post-lens (between the lens and cornea) 
compartments, with the post-lens compartment being of particular 
interest due to limited tear mixing and exchange [21,22]. As a result, 
drugs released from the CL into this compartment potentially have 
a prolonged contact time with the cornea, leading to improved 
bioavailability [23]. Over 50% of the drugs released from a CL can 
diffuse into the cornea, which is at least 35 times more efficient than 
eye drops [24]. This increase in efficiency permits substantially reduced 
concentrations to be used, decreasing the potential for side effects as 
less drug is absorbed systemically.
Another advantage to using a CL as a drug delivery platform is the 
ability to deliver drugs over extended time periods, which eliminates 
the need for multiple dosing. For ocular infections such as microbial 
keratitis, eye drop applications can be as frequent as applications every 
hour [25]. This can be very difficult for patients, especially during sleep, 
and severe infections often lead to hospitalization, purely to ensure 
appropriate drug administration [10,11]. Contact lenses effectively 
serve as a drug reservoir and release the drug over a set time period. 
In an ideal situation, the target drug forms an interaction with the CL 
polymer, and dissociates from the lens network in a time-dependent 
manner into the post-lens tear film, for eventual absorption by the 
ocular tissues.
Past Barriers - Contact Lenses Coming of Age
It is somewhat surprising that although the potential application of 
CLs for ocular drug delivery was suggested in the 1960s [26,27], there 
continues to be no commercial products available. The initial problem 
with this concept was that early Conventional Hydrogel (CH) CLs did 
not provide adequate oxygen transmission to the cornea, resulting in 
hypoxia-related complications during overnight wear, limiting their 
long term therapeutic potential [28,29]. This issue was eventually 
overcome in the late 1990s, when highly oxygen permeable Silicone 
Hydrogel (SH) CLs were introduced. These lenses permitted near-
normal corneal physiology during extended periods of wear [30,31], 
and the idea of CLs for drug delivery became all the more promising, 
with this significant hypoxic hurdle seemingly solved. 
Aside from oxygen delivery issues, the use of CLs for drug delivery 
also has another major obstacle. Simple drug loading methods, such 
as soaking a commercial CL in pharmaceutical preparations inevitably 
leads to rapid release kinetics [32]. While different CL material and 
drug combinations provide different release durations, the overall 
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time frame for drug release is in the order of minutes and is thus not 
clinically useful [20,33,34]. This is not surprising as commercial CLs 
are intended solely for refractive error correction, but they are not 
designed for release of pharmaceuticals. As a result, extensive research 
has been conducted in the past decade to develop CL materials capable 
of extended drug delivery, and the in vitro results so far have been 
very promising. Strategies such as molecular imprinting [35], vitamin 
E coatings [33] and nanoparticles [36,37] have been investigated and 
tested. These materials are designed to form interactions with the 
target drug molecule in a manner that promotes drug retention and 
slow release over time. Molecular imprinting creates specific drug 
recognition sites within the polymer through the use of molecular 
templates [35]. Vitamin E coatings form diffusion barriers within the 
lens, which forces the target drug to take long complex paths to diffuse 
from the lens [33]. Nanoparticles encapsulated with the target drug 
can be loaded and released from the CL, and the extended release is 
controlled by the degradation of the nanoparticles [36,37]. CL materials 
developed using these technologies are capable of releasing ophthalmic 
drugs for up to several days and even weeks, in some cases [33,35,37]. 
Future Barriers - Fine Tuning Drug Release Characteristics 
Although the issue of extended drug release has been partially 
solved with the development of novel CL materials, the kinetics are far 
from optimal. Currently, drug release from these materials has been 
primarily diffusion controlled and first-order kinetics are typically 
observed [33,35,36]. Thus, the rate of drug release is not constant over 
time, with the majority of the drug within the lens being delivered 
in the initial stages rather than at the end of the treatment period. It 
can, therefore, be very difficult to design therapies when the drug dose 
cannot be controlled for a specific time point. One potential solution to 
this problem is to use the CLs only for the duration in which the release 
kinetics are zero-order and thus a linear, predictable drug release rate. 
However, this is not an optimal solution, as it would require frequent 
lens replacement at time periods which may be inconvenient for the 
patient, and so development of CL materials capable of zero-order 
release kinetics at all time periods is still preferred. 
Aside from the development of the ‘ideal’ drug delivery device, 
other issues are also worthy of mention. Antibiotic resistance among 
ocular pathogens, due to misuse and overuse of topical antibiotics in 
the eye, improper dosing regimen, and extended duration of therapy, is 
becoming increasingly prevalent [38-40]. As such, continuous release 
of antimicrobials from a CL raises concerns in regards to microbial 
resistance. The continuous presence of the antibiotic at potentially 
sub-therapeutic concentrations can lead to selection pressures favoring 
resistant organisms [41]. One of the key considerations is the ability 
for some microbes (such as fungi) to develop resistant spores. Upon 
exposure to an antimicrobial agent, the vulnerable microbes are killed 
but the spores can continue to remain dormant and unaffected [42]. 
When the agent is removed, the spores become active and resume 
normal growth [42]. The current approach to drug delivery using CLs 
in which drugs are continuously released, may lead to the development 
of resistant spores. Pulse drug delivery systems, although still in their 
infancy, have addressed some of the problems in regards to microbial 
resistance. By delivering the drug in multiple-timed doses, this method 
offers greater efficacy in killing microbes at doses almost half that of 
conventional therapies [42]. This concept has not yet been adapted to 
CLs for drug delivery, and is worth considering for future development. 
Continuous drug release also raises concerns regarding ocular toxicity. 
Unlike conventional eye drops, drugs released from CLs become 
trapped beneath the post-lens tear film, and are not rapidly removed 
[23]. It could be argued that because CLs are more efficient than eye 
drops at delivering topical drugs, the amount of drug required to be 
released from CLs will be substantially less than eye drops. Based on 
this assumption, ocular toxicity should not be greater, and may even 
be lower when using CLs. However, it is important to keep in mind 
that the post-lens tear film formed when a CL is placed on the eye is 
only 4 microns thick [43]. Thus, even small concentrations of drug 
released into this micro-environment over extended periods could lead 
to unforeseen ocular toxicity, as concentrations may be reached that 
are many times what is currently available through the use of topical 
pharmaceutical agents. 
A major limitation in this field currently is a shortage of in vivo 
studies to validate the effectiveness of a CL-delivery platform. To our 
knowledge, there have only been two published animal studies using 
CLs to treat an ocular condition [37,38], both of which revealed that 
CLs provide better bioavailability and reduced systemic drug uptake 
compared to conventional eye drop treatment [44,45]. Further in vivo 
research is needed to help facilitate this technology into the clinical 
trial phase, and lead to the development of a viable commercial 
product.
Acceptance - Can it Reach Clinicians and Affect Clinical 
Practice?
From a scientific and clinical standpoint, drug delivering CLs 
could revolutionize the way ocular diseases are treated. Still, there is 
an underlying concern whether this treatment platform will be readily 
accepted by patients and clinicians alike. Considering that CL dropout 
is already a pressing problem for the CL industry [46-48], it may be 
difficult to convince a non-CL wearer to wear CLs, let alone wear it 
for extended periods. However, the CL market is anything but small, 
with approximately 140 million current CL wearers worldwide that 
could benefit from using this technology, should the need arise for 
therapeutic intervention [49,50]. In addition, many spectacle wearers 
who undergo refractive surgery are able to wear a bandage lens for a 
short period of time [14,17,18,51], demonstrating the potential short-
term success of a therapeutic lens to treat disease. The higher cost of 
using a drug-delivering CL compared to eye drops may also be a barrier, 
thus putting the onus on the prescribing practitioner to be an advocate 
of the technology such that the virtues of the treatment strategy can 
be appropriately communicated. Of final concern is that the patient 
population for this technology may not be the most appropriate for 
certain diseases (for example glaucoma and chronic inflammatory 
diseases), as they are often elderly, for whom the prevalence of CL wear 
is already poor due to lens intolerance and issues with CL insertion and 
removal, providing another potential barrier. 
Conclusion
There has been considerable progress in the past decade in 
developing a viable CL-drug delivery platform and future work must 
focus on demonstrating in vivo effectiveness using these technologies. 
Furthermore, using this system to deliver other therapeutic agents (such 
as wetting and comfort agents to enhance the CL wearing experience) is 
an area rife with potential discoveries. The successful development of a 
CL platform that can deliver therapeutically relevant amounts of topical 
ocular drugs over extended periods will change the way ocular diseases 
are treated. Though the cost of such a system will likely be higher 
initially than conventional eye drops, the effectiveness of the treatment 
and the reduction in the frequency of application will make this system 
commercially attractive to clinicians. 
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